Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecularly targeted therapies for acute myeloid leukemia
    Journal Article

    Stein, E. M.
    Hematology-American Society of Hematology Education Program (2015)

    Fulltext@MSK | Save
  • A phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in adults with relapsed or refractory leukemia: Safety, clinical activity, exposure and target inhibition
    Meeting Abstract

    Stein, E. M.; Garcia-Manero, G.; Rizzieri, D. A.; Tibes, R.; Berdeja, J. G.; Jongen-Lavrencic, M.; Altman, J. K.; Dohner, H.; Thomson, B.; Blakemore, S. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A phase 1 trial of SGN-CD33A as monotherapy in patients with CD33-positive acute myeloid leukemia (AML)
    Meeting Abstract

    Stein, A. S.; Walter, R. B.; Erba, H. P.; Fathi, A. T.; Advani, A. S.; Lancet, J. E.; Ravandi, F.; Kovacsovics, T. J.; DeAngelo, D. J.; Bixby, D.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: Results of a phase 1/2 trial
    Meeting Abstract

    Stein, E. M.; DiNardo, C.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Kantarjian, H. M.; Sekeres, M. A.; Fathi, A. T.; Flinn, I. W.; Frankel, A. E.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • SGN-CD33A plus hypomethylating agents: A novel, well-tolerated regimen with high remission rate in frontline unfit AML
    Meeting Abstract

    Fathi, A. T.; Erba, H. P.; Lancet, J. E.; Stein, E. M.; Walter, R. B.; DeAngelo, D. J.; Faderl, S.; Jillella, A. P.; Ravandi, F.; Advani, A. S.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study
    Meeting Abstract

    DiNardo, C.; de Botton, S.; Pollyea, D. A.; Stein, E. M.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I. W.; Altman, J. K.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • IDH2 inhibition in AML: Finally progress?
    Journal Article

    Stein, E. M.
    Best Practice and Research: Clinical Haematology (2015)

    Fulltext@MSK | Save
  • DH2 inhibitors in acute myeloid leukemia
    Meeting Abstract

    Coombs, C. C.; Stein, E. M.; Levine, R. L.; Tallman, M. S.
    Annals of Hematology (2015)

    Fulltext@MSK | Save
  • Ag-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies
    Meeting Abstract

    DiNardo, C.; Stein, E. M.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Fathi, A. T.; Flinn, I.; Frankel, A.; Levine, R. L.; Medeiros, B. C.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies
    Meeting Abstract

    de Botton, S.; Pollyea, D. A.; Stein, E. M.; DiNardo, C.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I.; Altman, J. K.; more...
    Haematologica (2015)

    Fulltext@MSK | Save